Stay at your current dose if you are losing 1 to 2 pounds per week, nausea is absent or mild, appetite suppression lasts the full week between injections, and your energy levels are stable
Archived (PDF) from the original on 26 January 2017
(PubMed) If AOD-9604 re-enters mainstream clinical availability through compliant channels, the most responsible use-case will likely be: carefully selected patients, realistic expectations, body composition focus, and as an adjunctnot a centerpiece
This work has significant implications for understanding muscle preservation during fat loss
Higher doses may be considered under clinical supervision for those who decline injections despite malabsorption, though this is an off-label approach
Thus, scientists must note that unanticipated reactions may emerge as research progresses